— Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a third-quarter 2019 loss of $0.21 per share versus a loss of $0.15 per share expected.
— Revenue plunged by 39% to $230,000 versus $50,000 expected. The top line was hurt by nil contract revenue.
— Research and development expenses soared by 59% due to the manufacturing of voclosporin for commercial and investigational use. It also includes costs related to the Aurora 2 extension study and other expenses.
— As looking forward to results from the Aurora Phase 3 trial for kidney inflammation lupus nephritis by the end of this year, the company has been preparing for success by continuing to strengthen the Board.
— Looking ahead to 2020, and assuming positive results, Aurinia plans on submitting an NDA in the first half of 2020 and projects a commercial launch of voclosporin in early 2021 as a potential first-line treatment for lupus nephritis.
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q1 2024
Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or
ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was